Transdermal Drug Delivery Market: By Technology; By Application, Pain Management, Cardiovascular, Others & By Region - Forecast 2017-2022

  • ID: 4033483
  • Report
  • 169 pages
  • IndustryARC
1 of 3
Transdermal drug delivery is a mode of drug administration in which a drug is applied in the form of a plaster, patch, or ointment and administered through a patient’s skin such that the drugs are gradually absorbed into the systemic circulation. Globally, development of efficient and advance technologies such as the inclusion of micro-needles or mechanical arrays in transdermal patches, rise in the awareness among people, increasing government initiatives across the globe, and growing preference of patients as well as physicians toward pain-free drug delivery are the prime growth drivers of the transdermal drug delivery market. In addition, an increase in adoption of transdermal drug delivery for peripheral artery diseases, and emerging economies such as China, India and others, will create new opportunities for the transdermal drug delivery market. However, higher cost of research and development, and higher cost of interventional devices are the key restraints for the transdermal drug delivery market.

Geographically, North America dominated the transdermal drug delivery market, with approximately half of the world’s procedures being done in the U.S. because of patent expirations, reformulation of existing drug compounds, repositioning of previously failed drugs, and huge investments undertaken by prominent as well as new market entrants. Asia Pacific is projected to have the fastest growth, owing to a rapidly increasing aging population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the applications, the cardiovascular segment has the fastest growth in the transdermal drug delivery market due to higher adoption of these systems in the treatment of angina pectoris, hypertension, and congestive heart failure.

This report identifies the transdermal drug delivery market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the transdermal drug delivery market.

This report segments the transdermal drug delivery market on the basis of technology, application, and regional market as follows:
Transdermal Drug Delivery Market, By Technology: Electroporation, Radio Frequency, Iontophoresis, Microporation, Thermal, Mechanical Arrays, Ultrasound, and Others
The report has focused study on transdermal drug delivery market by basis of application such as: Central Nervous System (CNS), Pain Management, Cardiovascular, Hormone Replacement Therapy, Contraception, and Smoking Cessation
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the transdermal drug delivery market. Some of the major companies’ profiles in detail are as follows:
Boehringer Ingelheim GmbH
Actelion Pharmaceuticals Ltd
Bayer Crop Science Ltd.

BioGel Technology Inc.

Upsher-Smith Laboratories, Inc.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Transdermal Drug Delivery Market – Overview

2. Executive Summary

3. Transdermal Drug Delivery Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Transdermal Drug Delivery Market– Forces
4.1. Drivers
4.1.1. Development of efficient and advance technologies such as the inclusion of microneedles or mechanical arrays in transdermal patches
4.1.2. Growing preference of patients as well as physicians toward pain-free drug delivery
4.2. Restraints
4.2.1. Higher cost of research and development
4.3. Opportunities
4.3.1. Emerging economies
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Transdermal Drug Delivery Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Transdermal Drug Delivery Market, By Technology
6.1. Electroporation
6.2. Radio Frequency
6.3. Iontophoresis
6.4. Microporation
6.5. Thermal
6.6. Mechanical Arrays
6.7. Ultrasound
6.8. Others

7. Transdermal Drug Delivery Market, By Application
7.1. Central Nervous System (CNS)
7.2. Pain Management
7.3. Cardiovascular
7.4. Hormone Replacement Therapy
7.5. Contraception
7.6. Smoking Cessation

8. Transdermal Drug Delivery Market, By Geography
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Transdermal Drug Delivery – Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Boehringer Ingelheim GmbH
10.2. Actelion Pharmaceuticals Ltd
10.3. Bayer Crop Science Ltd.
10.4. BioGel Technology Inc.
10.5. Upsher-Smith Laboratories, Inc.
10.6. 3M Pharmaceuticals Inc.
10.7. Johnson & Johnson Limited
10.8. Mylan Pharmaceuticals Inc.
10.9. GlaxoSmithKline plc
10.10. Novartis AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll